Widely-Used Cancer Drug Compounds Work Differently Than Scientists Thought

Two ferroptosis-inducing compounds long believed to fight cancer by targeting GPX4 actually work through a different protein pathway, TXNRD1. The discovery could reshape drug development strategies and improve efficacy of treatments in clinical pipelines relying on these mechanisms.

Originaltitel: The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1